With decades of hands-on experience, Sharp’s industry experts reveal their top five recommendations for a timely and ...

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

Though the FDA will continue its core activities, the agency will no longer be accepting NDAs and BLAs until the ...

During HUAWEI CONNECT 2025, Leo Chen, Senior Vice President, President of Enterprise Sales, Huawei, emphasised the focus is ...

Though unexpected CRLs issued by the FDA have caused ripples in the industry, Becky Wood believes that these cases are the ...

Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities ...

The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...

The US Government has shut down for the first time since 2018 after a majority of Democrat senators refused to back ...

As part of President Trump’s Most Favored Nation (MFN) policy, the company agreed to ensure that US patients are paying less ...

Orphan drugs are therapeutics developed to address rare diseases typically defined by patient population thresholds that vary ...

The Massachusetts bioresearch centre expansion is part of AbbVie’s wider ploy to bolster its US operations amid Trump tariff ...

Changing trends in the biopharma sector may mean new risks for established players and opportunities for growth, says BIA ...